青鸟生物宣布减少25%的劳动力,目标是到2025年实现财政稳定,重点是将LYFGENIA、ZYNTEGLO和SKYSONNA疗法商业化。 Bluebird Bio announces 25% workforce reduction, targets financial stability by 2025, and focuses on commercializing therapies LYFGENIA, ZYNTEGLO, and SKYSONA.
蓝鸟Bio是一家基因治疗公司,它宣布了一项重组计划,其中包括减少25%的劳动力,以便在2025年下半年实现财政稳定。 Bluebird Bio, a gene therapy company, has announced a restructuring plan that includes a 25% workforce reduction to achieve financial stability by the second half of 2025. 该倡议的目标是将现金业务开支减少20%,并侧重于将LYFGENIA、ZYNTEGLO和SKYSONNA疗法商业化。 The initiative aims for a 20% decrease in cash operating expenses and focuses on commercializing its therapies LYFGENIA, ZYNTEGLO, and SKYSONA. 林业发展局于2023年12月批准LYFGENIA治疗镰状细胞疾病,预计大约40名病人在2024年Q4开始治疗。 The FDA approved LYFGENIA in December 2023 for sickle cell disease, with about 40 patient starts expected in Q4 2024.